ReviewJournal of clinical medicine2021
Challenges in Acanthamoeba Keratitis: A Review.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- Article
- Efficacy of Imidazolium Salt in Disinfecting Soft Contact Lenses Contaminated with Acanthamoeba spp. Trophozoites.Acta parasitologica · 2026Article
- Genetic diversity of Acanthamoeba and clinical outcome predictors in Danish patients with Acanthamoeba keratitis.Acta ophthalmologica · 2026Article
- Article
- Anterior Segment Eye Diseases and Quality of Life: An Updated Comprehensive Narrative Review.Journal of ophthalmic & vision research · 2026Review
- Amoebicidal, anti-adhesive, and low-cytotoxic effects ofVeterinary world · 2025Article
- Silver(I)-NHC Complexes as Dual-Action Agents Against PathogenicInternational journal of molecular sciences · 2025Article
- Histopathologic Evaluation of Corneal Tissue After Adjunctive Rose Bengal Photodynamic Antimicrobial Therapy and Keratoplasty in Advanced Acanthamoeba Keratitis.Journal of clinical medicine · 2025Article
- Targets for the diagnosis ofmSphere · 2025Article
- The Antimicrobial Efficacy of Amine-Containing Surfactants Against Cysts and Trophozoites ofMicroorganisms · 2025Article
- Demographic Characteristics, Contributing Risk Factors, and Prognosis ofClinical ophthalmology (Auckland, N.Z.) · 2025Article
- The pathogenesis, risk factors, diagnosis and treatment of Acanthamoeba keratitis.Frontiers in medicine · 2025Review
- Article
- Acanthamoeba keratitis: from pathophysiology to prevention, a contemporary clinical perspective.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Review
- Oxford Nanopore Technology-Based Identification of anMicroorganisms · 2024Article
- Review
- Anti-Acanthamoeba metallopharmaceuticals: Amoebicidal activity and synergistic effect of copper(II) coordination compound.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Vermamoeba vermiformis as the etiological agent in a patient with suspected non-Acanthamoeba keratitis.Parasitology research · 2024Article
- Infectious eye disease in the 21st century-an overview.Eye (London, England) · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review challenges in the diagnosis and management of Acanthamoeba keratitis (AK), along with prognostic factors, in order to help ophthalmologists avoid misdiagnosis, protracted treatment periods, and long-term negative sequelae, with an overarching goal of improving patient outcomes and quality of life, we examined AK studies published between January 1998 and December 2019. All manuscripts describing clinical manifestations, diagnosis, treatment, prognosis, and challenges in short- and long-term management were included. The diagnosis of AK is often challenging. An increased time between symptom onset and the initiation of appropriate therapy is associated with poorer visual outcomes. The timely initiation of standardized antiamoebic therapies improves visual outcomes, decreases the duration of treatment, and reduces the chances of needing surgical intervention. In clinical practice, AK diagnosis is often missed or delayed, leading to poorer final visual outcomes and a negative impact on patient morbidity and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.